Overview

Positioning of Esketamine Treatment in the Real-world Management of Depression

Status:
Recruiting
Trial end date:
2026-01-15
Target enrollment:
Participant gender:
Summary
The goal of this naturalistic, open label, single arm intervention study is to investigate the effects of Esketamine in treating depression.The main aims to answer are: - to investigate whether Esketamine is effective when added to ongoing antidepressant treatment - to identify patient characteristics that will determine a therapeutic response to Esketamine in real-world practice Participants will: - attend the clinic for supervised self-administration of intranasal Esketamine treatment - be observed for 2 hours following Esketamine administration including blood pressure monitoring - be asked to complete a battery of questionnaires - be reimbursed for travel expenses
Phase:
Phase 4
Details
Lead Sponsor:
Royal North Shore Hospital
Collaborator:
Janssen-Cilag Pty Ltd
Treatments:
Esketamine